OwlTail

Cover image of 4th IMPAKT Breast Cancer Conference

4th IMPAKT Breast Cancer Conference

4th IMPAKT Breast Cancer Conference

Weekly hand curated podcast episodes for learning

Popular episodes

All episodes

Warning: This podcast data isn't working.

This means that the episode rankings aren't working properly. Please revisit us at a later time to get the best episodes of this podcast!

Podcast cover

PI3K and the heterogeneity of small tumour breast cancer: Dr Sherene Loi – Jules Bordet Institute, Brussels, Belgium

Dr Sherene Loi talks to ecancer about the heterogeneity of breast cancer tumours at IMPAKT 2012 in Brussels, May 2012. Technology now allows for the understanding of the cancer genome down to the base pair of certain types of cancer. In small tumour breast cancer, less than 2cm, the tumours have multiple ‘clones’ and these ‘clones’ drive the growth of the tumour. Treatment of one tumour can be the reason for relapses as another tumour can then proliferate. Dr Loi also discusses PI3 kinase, which is essential for cell growth but highly irregular in breast cancer and especially in triple negative breast cancer where no targeted therapies yet exist.

5mins

30 May 2012

Rank #1

Podcast cover

Metabolism in malignant tumors: Prof Tak Mak - University of Toronto, Canada

Prof Tak talks to ecancer at the IMProving care And Knowledge through Translational research (IMPAKT) meeting in Brussels, May 2012, about his insights in to the basis for molecular therapy. Prof Tak uses an analogy of oncogenes being the 'horses' pulling the 'cart' of cancer.Prof Tak points out that while it looks promising to target any one of the hundreds of oncogenes which cause cancer, they essentially all result in the same 2 or 3 metabolic pathways so perhaps we should be investigating the metabolism processes instead, as a potential for a 'catch-all' treatment.

8mins

30 May 2012

Rank #2

Podcast cover

Evidence for TORC1 activation marker as a predictive factor for everolimus: Dr Thomas Bachelot - Centre Leon Berard, France

A new analysis may help doctors identify breast cancer patients who will benefit from treatment with the immune suppressant drug everolimus, said French researchers at the 4th IMPAKT Breast Cancer Conference in Brussels, Belgium.Everolimus is currently used as an immunosuppressant to prevent patients rejecting transplanted organs and in the treatment of renal cell cancer. Research is also being conducted into the drug’s use in other cancers, including breast cancer.Dr Thomas Bachelot, from Centre Leon Berard in Lyon and colleagues analyzed data from the TAMRAD study, published two years ago

7mins

30 May 2012

Rank #3

Podcast cover

Targeting DNA damage response and repair for triple negative breast cancer: Prof Thomas Helleday - Karolinska Institutet, Swede

Prof Helleday talks to ecancer at the IMProving care And Knowledge through Translational research (IMPAKT) meeting in Brussels, May 2012, about novel therapies for triple negative breast cancer including the use of 6-mercaptopurine, previously not used in this group of patients.The plan is to tackle cells which have been resistant to cisplatin or PARP inhibitors; Prof Helleday discusses studies underway.

5mins

30 May 2012

Rank #4

Most Popular Podcasts

Podcast cover

New cyclin-dependent kinase inhibitor with letrozole for ER+/HER2- breast cancer: Prof Richard Finn - Universtity of California

Prof Finn talks to ecancer at at the IMProving care And Knowledge through Translational research (IMPAKT) meeting in Brussels, May 2012, about the results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for firstline treatment of ER+/HER2- advanced breast cancer.The new compound has the potential to be a standard of care in this setting, if a phase 3 study is successful, and also has promise in the adjuvant setting.

7mins

29 May 2012

Rank #5

Podcast cover

Endocrine therapy and endocrine resistant breast cancer: Prof Mitch Dowsett – The Institute for Cancer Research, London, UK

Prof Mitch Dowsett talks to ecancer about important papers presented at IMPAKT 2012 in Brussels, May 2012, on endocrine therapy, drug resistance, cell cycling and combination therapy. Prof Dowsett discusses findings on everolimus, data from the BOLERO-2 study, which was presented by Prof Jose Baselga, and the outcomes from a phase 2 study involving CDK inhibitors.

7mins

29 May 2012

Rank #6

Podcast cover

Neoadjuvant therapy and PCR through chemotherapy prior to surgery: Dr Michail Ignatiadis – Jules Bordet Institute, Belgium

Prof Michail Ignatiadis talks to ecancer about neoadjuvant therapy and pathological complete response (PCR) at IMPAKT 2012 in Brussels, May 2012. The study conducted looks at whether or not neoadjuvant therapy should be used in order to reach pathological complete response. Results have shown that this can occur after commonly used therapies. Data shows that patients with HER2 amplified and triple negative tumours have excellent response when receiving chemotherapy before surgery. After treatment, biopsies can be used to determine tumour type and its sensitivity to chemotherapy for future record. The most important finding in the study was that the immune response module had a signficantly higher probability of complete pathological response.

6mins

29 May 2012

Rank #7

Podcast cover

Endocrine therapy resistance and next generation sequencing: Prof Matthew Ellis - Washington University, USA

Prof Ellis talks to ecancer at the IMProving care And Knowledge through Translational research (IMPAKT) meeting in Brussels, May 2012, about the molecular complexity of endocrine therapy resistance and the potential of next generation sequencing to facilitate drug development.

9mins

29 May 2012

Rank #8

Podcast cover

Highlights and goals of IMPAKT 2012: Prof Martine Piccart – Jules Bordet Institute, Brussels, Belgium

Prof Martine Piccart talks to ecancer about heterogeneity of breast cancer tumours, advancements in technology and the future of treating breast cancer at IMPAKT 2012 in Brussels, May 2012. IMPAKT 2012 focused on the latest developments in translational research, teaching young oncologists on how to treat patients in the coming years and especially on the heterogeneity of tumours. New technologies hold the potential for understanding the evolution of breast cancer and the differences between primary tumours and metastases. With HER+ tumours, each type of tumour, slow growing and highly proliferating, hold very specific molecular characteristics that can potentially unlock new understandings of the disease through the patient's immune system and the microenvironment.

6mins

29 May 2012

Rank #9

Podcast cover

Targeting the PI3K/mTOR pathway: Dr Lewis Cantley – Dana-Farber Cancer Institute, Boston, USA

Dr Lewis Cantley talks to ecancer about PI3K and the development of inhibitors for clinical use at IMPAKT 2012 in Brussels, May 2012. PI3K, phosphoinosititde 3-kinase is a signalling pathway that controls growth. PI3K is the most frequently mutated gene in breast cancer. Currently, there are 20 inhibitors in phase 1 or 2 trials. Dr Cantley mentions that there has been good response in phase 1 trials, but while many patients had very good reactions, others did not respond. The message to take away from this is that doctors should be more aggressive in doing mutational analyses and, more importantly, that this information become more accessible for retroactive analysis for other targetable mutations.

6mins

29 May 2012

Rank #10